First-line datopotamab deruxtecan (Dato-DXd) not only improved survival outcomes vs chemotherapy but also delivered sustained quality-of-life benefits (QoL) for patients with locally recurrent, ...
Los enormes centros de datos que impulsan la inteligencia artificial devoran enormes cantidades de energía, pero también tienen otro impacto alarmante, según una nueva investigación. Están creando ...
Red Eléctrica has launched real-time, setpoint-based voltage control services, enabling renewable energy installations to provide dynamic grid support, according to data published on its Esios ...
Frente a la compleja herencia fiscal que enfrenta el nuevo gobierno, los exministros Marcel y Grau han desplegado un arsenal de argumentos: cuestionar el mes elegido para medir la caja, atribuir el ...
Peggy A. Datillo, 70, of De Soto died Dec. 2, 2025, at her home. Mrs. Datillo enjoyed swimming at Briarwood Lake, hiking, and spending time with family and friends. She is survived by her husband of ...
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event. There ...
Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy. The FDA has granted accelerated approval to the ...
Yema has given its iconic diver a thoughtful upgrade with the new Superman Dato CMM.10, which appears to be a quiet evolution in design and mechanics rather than a radical departure. Available in two ...
¿Te gusta jugar en familia o con amigos? ¡A nosotras también! Entre los juegos que más nos gustan (además de los que seleccionamos para nuestro artículo de mejores juegos de mesa para jugar con amigos ...
With 42 years of experience, Dato' Lau leads the health care division of the Sunway Group. Sunway Healthcare Group (SHG) currently has five hospitals around Malaysia, specialist day ambulatory care ...
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results